Keros Therapeutics (KROS) Misses Q4 EPS by 16c
Tweet
Share
E-mailGet Alerts KROS Hot Sheet
Join SI Premium – FREE
Keros Therapeutics (NASDAQ: KROS) reported Q4 EPS of ($0.86), $0.16 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $385 thousand versus the consensus estimate of $2.76 million.
For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA maintains underperform ratings on six BDC stocks
- CoVolt Power files for proposed IPO
- Myriad Uranium completes acquisition of Rush Rare Metals
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
